Dr. Heilbrunn has served as our Senior Vice President, Clinical Development since April 2005. From May 2002 to April 2005, Dr. Heilbrunn served as Vice President of Clinical Development of La Jolla Pharmaceutical Company, an autoimmune disease-focused biopharmaceutical company. From 1998 to April 2002, he held several positions, the most recent of which was Vice President of Clinical Research, at Advanced Tissue Sciences, Inc., a tissue engineering company, where he was responsible for a multicenter Phase III clinical trial which ultimately led to the FDA approval of Dermagraft, a bioengineered human tissue. From 1997 to 1998, Dr. Heilbrunn served as Vice President of Medical Affairs at Hepatix, Inc., a company engaged in the development of a bioengineered liver. From 1994 to 1996, he served as Staff Vice President of Medical Affairs at C.R. Bard, Inc., a manufacturer of healthcare products. From 1989 to 1994, he held several positions in the Medical Affairs department of Ciba-Geigy Pharmaceuticals Division, a pharmaceutical company, the most recent of which was Director for Cardiovascular and Pulmonary Drugs, where he participated in the launch of the nicotine patch, Habitrol, and the antihypertensive drug, Lotensin. From 1986 to 1989, Dr. Heilbrunn served as Staff Internist and, ultimately, Director of the Critical Care unit at the 31st Tactical Air Force Hospital in Homestead, Florida. Dr. Heilbrunn received a B.A. from Brown University and an M.D. from New York Medical College.